Literature DB >> 21694688

ampliPHOX colorimetric detection on a DNA microarray for influenza.

Kevin R Moulton1, Amber W Taylor, Kathy L Rowlen, Erica D Dawson.   

Abstract

DNA microarrays have emerged as a powerful tool for pathogen detection. For instance, many examples of the ability to type and subtype influenza virus have been demonstrated. The identification and subtyping of influenza on DNA microarrays has applications in both public health and the clinic for early detection, rapid intervention, and minimizing the impact of an influenza pandemic. Traditional fluorescence is currently the most commonly used microarray detection method. However, as microarray technology progresses towards clinical use, replacing expensive instrumentation with low cost detection technology exhibiting similar performance characteristics to fluorescence will make microarray assays more attractive and cost-effective. The ampliPHOX colorimetric detection technology is intended for research applications, and has a limit of detection within one order of magnitude of traditional fluorescence, with a main advantage being an approximate ten-fold lower instrument cost compared to the confocal microarray scanners required for fluorescence microarray detection. Another advantage is the compact size of the instrument which allows for portability and flexibility, unlike traditional fluorescence instruments. Because the polymerization technology is not as inherently linear as fluorescence detection, however, it is best suited for lower density microarray applications in which a yes/no answer for the presence of a certain sequence is desired, such as for pathogen detection arrays. Currently the maximum spot density compatible with ampliPHOX detection is ˜1800 spots/array. Because of the spot density limitations, higher density microarrays are not suitable for ampliPHOX detection. Here, we present ampliPHOX colorimetric detection technology as a method of signal amplification on a low density microarray developed for the detection and characterization of influenza viruses (FluChip). Although this protocol uses the FluChip (a DNA microarray) as one specific application of ampliPHOX detection, any microarray incorporating biotinylated target can be labeled and detected in a similar manner. The microarray design and biotinylation of the target to be captured are the responsibility of the user. Once the biotinylated target has been captured on the array, ampliPHOX detection can be performed by first tagging the array with a streptavidin-label conjugate (ampliTAG). Upon light exposure using the ampliPHOX Reader instrument, polymerization of a monomer solution (ampliPHY) occurs only in regions containing ampliTAG-labeled targets. The polymer formed can be subsequently stained with a non-toxic solution to improve visual contrast, followed by imaging and analysis using a simple software package (ampliVIEW). The entire FluChip assay from un-extracted sample to result can be performed in about 6 hours, and the ampliPHOX detection steps described above can be completed in about 30 min.

Entities:  

Mesh:

Year:  2011        PMID: 21694688      PMCID: PMC3197038          DOI: 10.3791/2682

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  11 in total

Review 1.  Challenges and opportunities for pathogen detection using DNA microarrays.

Authors:  Douglas R Call
Journal:  Crit Rev Microbiol       Date:  2005       Impact factor: 7.624

2.  Antigen detection using polymerization-based amplification.

Authors:  Hadley D Sikes; Robert Jenison; Christopher N Bowman
Journal:  Lab Chip       Date:  2008-12-08       Impact factor: 6.799

3.  Photopolymerization as an innovative detection technique for low-density microarrays.

Authors:  Laura R Kuck; Amber W Taylor
Journal:  Biotechniques       Date:  2008-08       Impact factor: 1.993

Review 4.  Basic concepts of microarrays and potential applications in clinical microbiology.

Authors:  Melissa B Miller; Yi-Wei Tang
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

5.  Experimental evaluation of the FluChip diagnostic microarray for influenza virus surveillance.

Authors:  Michael B Townsend; Erica D Dawson; Martin Mehlmann; James A Smagala; Daniela M Dankbar; Chad L Moore; Catherine B Smith; Nancy J Cox; Robert D Kuchta; Kathy L Rowlen
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

6.  Rapid haemagglutinin subtyping and pathotyping of avian influenza viruses by a DNA microarray.

Authors:  Astrid Gall; Bernd Hoffmann; Timm Harder; Christian Grund; Ralf Ehricht; Martin Beer
Journal:  J Virol Methods       Date:  2009-05-15       Impact factor: 2.014

7.  Use of the DNA flow-thru chip, a three-dimensional biochip, for typing and subtyping of influenza viruses.

Authors:  Nicole Kessler; Olivier Ferraris; Kevin Palmer; Wayne Marsh; Adam Steel
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

8.  Development of fluorescent polymerization-based signal amplification for sensitive and non-enzymatic biodetection in antibody microarrays.

Authors:  Heather J Avens; Christopher N Bowman
Journal:  Acta Biomater       Date:  2009-06-07       Impact factor: 8.947

9.  Identifying influenza viruses with resequencing microarrays.

Authors:  Zheng Wang; Luke T Daum; Gary J Vora; David Metzgar; Elizabeth A Walter; Linda C Canas; Anthony P Malanoski; Baochuan Lin; David A Stenger
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

Review 10.  What does the future hold for clinical microbiology?

Authors:  Didier Raoult; Pierre Edouard Fournier; Michel Drancourt
Journal:  Nat Rev Microbiol       Date:  2004-02       Impact factor: 60.633

View more
  1 in total

1.  O-antigen and virulence profiling of shiga toxin-producing Escherichia coli by a rapid and cost-effective DNA microarray colorimetric method.

Authors:  Beatriz Quiñones; Michelle S Swimley; Koh-Eun Narm; Ronak N Patel; Michael B Cooley; Robert E Mandrell
Journal:  Front Cell Infect Microbiol       Date:  2012-05-11       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.